Concept illustration only. It is not a SPARDER test result or a representation of a finished product.

Terms such as liposome, microencapsulation, nanoemulsion and phospholipid complex appear increasingly often in supplement development. They may address practical challenges—including limited dispersibility or sensitivity to light, oxygen, temperature and gastrointestinal conditions—but a technology name alone does not establish the performance of a finished product. The more useful question is whether the particular ingredient, formulation and dosage form have been characterized and tested under relevant conditions.

What should be checked for a liposomal system?

A liposome is generally described as a vesicle formed by one or more phospholipid bilayers. The presence of phospholipids in an ingredient list, or a single small average particle-size result, does not by itself prove that the intended vesicle structure exists in the final formulation. Composition and processing conditions can change that structure.

Evaluation should consider structural characterization, particle-size distribution rather than the average alone, the proportion of target material actually encapsulated, and changes during storage and transport. A promising result immediately after manufacture is not a substitute for a stability trend at relevant time points.

Ingredient stability is not finished-product stability

An ingredient supplier's data usually describe a defined material under defined test conditions. Once that material is combined with other ingredients, flavours, sweeteners, water or packaging, the environment changes. Product development therefore needs to distinguish ingredient stability, formula compatibility and finished-product stability.

For example, a microencapsulated oil intended for powder sticks raises questions about moisture uptake, powder flow, blend uniformity and package barrier performance. A tablet may expose the system to compression force. Gummies bring heat, acidity and water activity into consideration; oral liquids introduce different water and pH conditions. No delivery system has a universal stability result independent of the final dosage form.

Microencapsulation is a family of approaches

Microencapsulation can use different materials and processes, including spray drying, emulsion-based systems and protein–polysaccharide or lipid carriers. The design goal may be to reduce oxidation, improve powder handling, mask an unwanted taste or adapt release under specified conditions. These goals are not interchangeable. Before choosing a route, a brand and its OEM/ODM partner should identify the actual problem to solve and the measurable acceptance criteria.

Use absorption claims with care

Research on a particular ingredient or delivery system cannot automatically be transferred to every commercial product. Dose, formulation, comparator, analytical method, study population and use conditions all affect the interpretation of bioaccessibility or bioavailability data. Claims such as “X times better absorption” require evidence applicable to the product and market in question; they should not be copied from an ingredient brochure without checking those conditions.

From laboratory concept to repeatable manufacture

Scale-up adds further questions: batch consistency, shear and temperature exposure, equipment suitability, cleaning, ingredient supply, cost and product documentation. A practical evaluation path is ingredient characterization → formula compatibility → dosage-form and process assessment → finished-product stability → market-specific regulatory review. This is why delivery technology, dosage form and manufacturing process need to be evaluated together.

SPARDER follows developments in softgels, tablets, hard capsules, gummies, powders and oral liquids from this product-development perspective. The appropriate route depends on the actual ingredient and the proposed final product; no performance benefit is implied for a SPARDER product without corresponding product-specific evidence.

Frequently asked questions

What is a supplement delivery system?
A carrier or formulation approach intended to protect, disperse or control the release of an ingredient under specified conditions.

Is particle size enough to identify a liposome?
No. Structure, size distribution, encapsulation and stability should be considered together.

Must a microencapsulated ingredient be reassessed in the final product?
Yes. Processing and the final formulation can alter the behaviour seen in ingredient-level tests.

Does an advanced delivery system always improve bioavailability?
No. That conclusion depends on evidence for the specific ingredient, formulation, dose and test conditions.

What should an OEM/ODM manufacturer evaluate?
Ingredient specifications, formula compatibility, dosage-form fit, processing feasibility, stability, scale-up and applicable market requirements.